Biogen IDEC (BIIB) and partner Swedish Orphan Biovitrum (BIOVF.PK) see positive top-line results...


Biogen IDEC (BIIB) and partner Swedish Orphan Biovitrum (BIOVF.PK) see positive top-line results from a study of their clotting factor candidate for patients with hemophilia B. The recombinant Factor IX Fc fusion protein was "generally well tolerated" and offers a more long-lasting treatment than current therapies requiring up to three intravenous injections a week. BIIB +2.4% premarket.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs